Current Clinical Trials

Department: Gastroenterology
Diagnosis: Gastrointestinal - Ulcerative Colitis
Principal Investigator: Georgetson MD, FACG, Michael
Sponsor: Janssen
Details (Identifier #): NCT02407236
Title: CNTO1275UCO3001, A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Walsh MD, James
Sub-Investigator(s):
Sponsor: OncoCyte
Details (Identifier #): none
Title: ONC-LN-04, A study to Evaluate a Panel of Blood Biomarkers for Use in Patients Undergoing Evaluation for Lung Cancer
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lowry MD, Philip
Sponsor: BMS
Details (Identifier #): NCT02477826
Title: CA209227: An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Department: Neurology
Diagnosis: Neurology
Principal Investigator: Meyer MD, Michael
Sub-Investigator(s):
Sponsor: ACRIN
Details (Identifier #): NCT02420756
Title: Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study: A Coverage with Evidence Development Longitudinal Cohort Study
Department: Gastroenterology
Diagnosis: Gastrointestinal - Crohn's
Principal Investigator: Georgetson MD, FACG, Michael
Sponsor: Salix
Details (Identifier #): NCT02240121
Title: A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional Study to Assess the Efficacy and Safety of Rifaximin Delayed Release Tablets for the Induction and Maintenance of Remission in Subjects with Active Moderate Crohn's Disease (RECD3125)
Department: Oncology
Diagnosis: Lung- Small Cell
Principal Investigator: Lowry MD, Philip
Sponsor: BMS
Details (Identifier #): NCT02538666
Title: CA209-451-0002, A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) after Completion of Platinum-based First Line Chemotherapy
Department: Arrhythmia Center
Diagnosis: Cardiac - Arrhythmia
Principal Investigator: Deshmukh MD, Pramod
Sub-Investigator(s):
Sponsor: Internal FDN
Details (Identifier #): NCT02931253
Title: Metformin as an Upstream Therapy in Atrial Fibrillation
Department: Oncology
Diagnosis: Gastrointestinal - Pancreas
Principal Investigator: Lowry MD, Philip
Sponsor: RTOG
Details (Identifier #): NCT01013649
Title: RTOG0848, A Phase II-R and A Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma
Department: Oncology
Diagnosis: Hematology- Multiple Myeloma
Principal Investigator: Lowry MD, Philip
Sponsor: BMS
Details (Identifier #): NCT02726581
Title: BMS CA209-602, A Phase 2/3 Trial Combining Nivolumab, Elotuzumab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Department: Surgery
Diagnosis: Gastrointestinal - Miscellaneous
Principal Investigator: Sadik MD, Karim
Sponsor: Internal FDN
Details (Identifier #): NCT02250924
Title: Prospective, Randomized caffeinated Gum to Prevent Post-Operative Ileus: A , Placebo-controlled trial
Department: Cardiology
Diagnosis: Cardiac - Congestive Heart Failure
Principal Investigator: Sporn M.D., Daniel
Sponsor: Janssen
Details (Identifier #): NCT01877915
Title: Commander HF, A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Oral Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Chronic Heart Failure and Significant Coronary Artery Disease Following a Hospitalization for Exacerbation of Heart Failure
Department: Oncology
Diagnosis: Head and Neck
Principal Investigator: Lowry MD, Philip
Sponsor: BMS
Details (Identifier #): NCT02823574
Title: BMS CA209-714,A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in combination with Ipilimumab placebo Squamous Cell Carcinoma of the Head and Neck (SCCHN) (CheckMate 714: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 714)
Department: Cardiology
Diagnosis: Cardiac - Surgery
Principal Investigator: Sporn M.D., Daniel
Sponsor: Abbott VD
Details (Identifier #): n/a
Title: GRAFTMASTER® RX Coronary Stent Graft System(JOSTENT)
Department: Oncology
Diagnosis: Lung- Miscellaneous
Principal Investigator: Lowry MD, Philip
Sponsor: SWOG
Details (Identifier #): NCT02154490
Title: S1400, Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lowry MD, Philip
Sponsor: BMS
Details (Identifier #): NCT02869789
Title: BMS CA209-817, A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer
Department: Gastroenterology
Diagnosis: Gastrointestinal - Ulcerative Colitis
Principal Investigator: Srivatana M.D., Ukorn
Sub-Investigator(s):
Sponsor: AbbVie
Details (Identifier #): NCT01848561
Title: Legacy P11-282, A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis (UC)
Department: Oncology
Diagnosis: Breast- Metastatic
Principal Investigator: Thakar MD, Keyur
Sponsor: SWOG
Details (Identifier #): NCT02595905
Title: S1416, Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
Department: Pulmonary
Diagnosis: Lung - COPD
Principal Investigator: Walsh MD, James
Sub-Investigator(s):
Sponsor: GSK
Title: Post-authorisation Safety (PAS) Observational Cohort Study to Quantify the Incidence and Comparative Safety of Selected Cardiovascular and Cerebrovascular Events in COPD Patients Using Inhaled UMEC/VI Combination or Inhaled UMEC versus Tiotropium (Study 201038)
Department: Endocrinology
Diagnosis: Diabetes
Principal Investigator: Kissell MD, Kerri
Sponsor: Sanofi Aventis
Details (Identifier #): NCT02451137
Title: LPS14347, A randomized, open-label, parallel group real world pragmatic trial to assess the clinical and health outcomes of Toujeo® compared to commercially available basal insulins for initiation of therapy in insulin naïve patients with uncontrolled type 2 diabetes mellitus
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lowry MD, Philip
Sponsor: SWOG
Details (Identifier #): NCT02642042
Title: S1507, A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Department: Oncology
Diagnosis: Breast- Metastatic
Principal Investigator: Lowry MD, Philip
Sponsor: Celldex
Details (Identifier #): NCT01997333
Title: CDX011-04, A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer
Department: Gastroenterology
Diagnosis: Gastrointestinal - Crohn's
Principal Investigator: Georgetson MD, FACG, Michael
Sponsor: MedImm
Details (Identifier #): NCT02574637
Title: DC5170C00002, A Phase 2b Double-blind, Multi-dose, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti-tumor Necrosis Factor-alpha Therapy
Department: Gastroenterology
Diagnosis: Gastrointestinal - Crohn's
Principal Investigator: McDonald M.D., Thomas
Sponsor: Eli Lilly
Details (Identifier #): NCT02891226
Title: 16T-MC-AMAG, A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
Department: Gastroenterology
Diagnosis: Gastrointestinal - Miscellaneous
Principal Investigator: McDonald M.D., Thomas
Sponsor: Janssen
Details (Identifier #): none
Title: Limited access protocol for the use of oral cisapride in the treatment of refractory gastroesophageal reflux disease and other gastrointestinal motility disorders. CIS-USA-154
Department: Cardiology
Diagnosis: Cardiac - Congestive Heart Failure
Principal Investigator: Sattur MD, Sudhakar
Sub-Investigator(s):
Sponsor: Astra Zeneca
Details (Identifier #): PENDING
Title: AstraZeneca D1680C00016, MEASURE-HF, MEchAniStic evalUation of glucose-loweRing strategiEs in patients with Heart Failure; A 24-Week, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Effects of Saxagliptin and Sitagliptin in Patients with Type 2 Diabetes Mellitus and Heart Failure
Department: Gastroenterology
Diagnosis: Gastrointestinal - Liver
Principal Investigator: McDonald M.D., Thomas
Sponsor: Gilead Sciences
Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis
Department: Oncology
Diagnosis: Breast
Principal Investigator: Thakar MD, Keyur
Sponsor: ECOG
Details (Identifier #): NCT02115282
Title: E2112, A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Department: Cardiology
Diagnosis: Miscellaneous
Principal Investigator: Deshmukh MD, Pramod
Sub-Investigator(s):
Sponsor: Duke
Title: His Bundle Pacing is Feasible and Superior to Right Ventricular Pacing in Patients with Bradycardia and Preserved Ejection Fraction: A Multi-Center Retrospective Registry of His Bundle Pacing: MR-HIS
Department: Gastroenterology
Diagnosis: Gastrointestinal - Liver
Principal Investigator: McDonald M.D., Thomas
Sponsor: Gilead Sciences
Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)
Department: Oncology
Diagnosis: Breast
Principal Investigator: Thakar MD, Keyur
Sponsor: ALLIANCE
Details (Identifier #): NCT02750826
Title: Alliance A011401, Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lowry MD, Philip
Sponsor: ECOG
Details (Identifier #): NCT02201992
Title: E4512, A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Department: Cardiology
Diagnosis: Cardiac - Arrhythmia
Principal Investigator: Deshmukh MD, Pramod
Sponsor: St. Jude Medical
Details (Identifier #): none
Title: MRI Diagnostic Registry IDE: A Clinical Evaluation of the Diagnostic Utility of MRI scans in patients implanted with St. Jude Medical pacemakers, ICDs, or CRTs.
Department: ENT
Diagnosis: Head and Neck
Principal Investigator: Clark M.D., Michael
Sub-Investigator(s):
Sponsor: Entellus
Details (Identifier #): N/A
Title: TEMPO Study
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lowry MD, Philip
Sponsor: ALLIANCE
Details (Identifier #): NCT02193282
Title: A081105, Randomized Study of Erlotinib or Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Department: Oncology
Diagnosis: Breast
Principal Investigator: Thakar MD, Keyur
Sponsor: ECOG
Details (Identifier #): NCT02445391
Title: EA1131, A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Department: Oncology
Diagnosis: Breast- Metastatic
Principal Investigator: Lowry MD, Philip
Sponsor: MacroGenics
Details (Identifier #): NCT02492711
Title: MacroGenics SOPHIA, CP-MGAH22-04, A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lowry MD, Philip
Sponsor: Mirati
Details (Identifier #): NCT02544633
Title: Mirati 265-109 Amethyst, A Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lowry MD, Philip
Sponsor: ALLIANCE
Details (Identifier #): NCT02194738
Title: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lowry MD, Philip
Sponsor: ECOG
Details (Identifier #): NCT02595944
Title: EA5142, Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lowry MD, Philip
Sponsor: Mirati
Details (Identifier #): NCT02219711
Title: Mirati Therapeutics Inc., 516-001: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies
Department: Neurology
Diagnosis: Neurology
Principal Investigator: Jasti MD, Venkata
Sub-Investigator(s):
Sponsor: Duke
Details (Identifier #): NCT02478177
Title: Management of Acute Stroke Patients on Treatment with New Oral Anticoagulants: Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry"
Department: Oncology
Diagnosis: Melanoma
Principal Investigator: Lowry MD, Philip
Sponsor: ECOG
Details (Identifier #): NCT02224781
Title: EA6134, A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Thakar MD, Keyur
Sub-Investigator(s):
Sponsor: NCI
Details (Identifier #): NCT02446600
Title: NRG-GY004, A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
Department: Gastroenterology
Diagnosis: Gastrointestinal - Ulcerative Colitis
Principal Investigator: Georgetson MD, FACG, Michael
Sponsor: AbbVie
Details (Identifier #): NCT02819635
Title: AbbVie M14-234, A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
Department: Oncology
Diagnosis: Melanoma
Principal Investigator: Lowry MD, Philip
Sponsor: ECOG
Details (Identifier #): NCT02339571
Title: EA6141, Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Thakar MD, Keyur
Sponsor: NCI
Details (Identifier #): NCT02502266
Title: Protocol NRG-GY005,A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)
Department: Oncology
Diagnosis: Hematology- Lymphoma
Principal Investigator:
Sponsor: Roche
Details (Identifier #): NCT02624986
Title: BH29812, A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Idasanutlin in Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B-Cell Lymphoma
Department: Oncology
Diagnosis: Lung- Small Cell
Principal Investigator: Lowry MD, Philip
Sponsor: G1Therapeutics
Details (Identifier #): NCT02499770
Title: G1T28-02; Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin Chemotherapy
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lowry MD, Philip
Sponsor: NSABP Foundation
Details (Identifier #): NCT02664077
Title: NSABP C-13, A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients with Stage III Colon Cancer (ARGO)
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator:
Sub-Investigator(s):
Sponsor: Internal
Details (Identifier #): none
Title: A Humanitarian Device Exemption Use Protocol of TheraSphere For Treatment of Unresectable Primary or Secondary Liver Neoplasia
Department: Oncology
Diagnosis: Lung- Small Cell
Principal Investigator: Lowry MD, Philip
Sponsor: G1Therapeutics
Details (Identifier #): NCT02514447
Title: Protocol G1T28-03, "Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy"